AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
AC Immune SA (NASDAQ: ACIU) reported interim 12-month Phase 1b/2 ABATE trial data for ACI-24 in 74 prodromal Alzheimer’s patients across AD1–AD3 cohorts. Company said ACI-24 was generally safe and well tolerated with no ARIA-E and anti–Abeta antibodies detected at all dose levels with a dose response. AD4 is ongoing with an added adjuvant; Takeda has an option/license agreement.
How this was made
The 30-second read
Why it matters
The company discloses interim 12-month safety and immunogenicity findings for AD1-3 (no ARIA-E; antibodies detected at all dose levels with dose response) and confirms AD4 initiation with an enhanced adjuvant, which can shift perceived clinical risk and expectations for the program’s next readout.
Market read
Traders may reprice ACIU’s clinical-risk profile based on interim safety (no ARIA-E) and immunogenicity (dose-response antibodies) plus the concrete next cohort (AD4) with an added adjuvant.
What to watch
ARIA-E absence is encouraging, but the sample is interim (first three cohorts) and the enhanced-adjuvant AD4 results are still pending; investors may discount the signal until efficacy or longer follow-up emerges.
Background
AC Immune’s ACI-24 is an anti-amyloid beta active immunotherapy in the Phase 1b/2 ABATE trial for prodromal Alzheimer’s disease; AD4 is evaluating an additional adjuvant to boost immunogenicity.
Ticker impact
AC Immune reports interim 12-month Phase 1b/2 ABATE data for ACI-24, saying it was generally safe with no ARIA-E and dose-response antibodies across AD1-3.
Likely supportive for ACIU sentiment in the near term, though magnitude depends on broader market appetite for Alzheimer’s immunotherapy risk.
The release provides concrete trial readouts (no ARIA-E; antibody detection at all doses; dose-response) and a clear next step (AD4 with additional adjuvant), which can move biotech risk perception even without efficacy endpoints.
Market effects
Adds incremental evidence for anti-amyloid active immunotherapy approaches in prodromal Alzheimer’s, potentially influencing sentiment around similar programs.
Limited direct regional spillover; primarily impacts US-listed biotech risk appetite for neurodegeneration trials.
Moderate global relevance given Alzheimer’s trial readouts and Takeda partnership context, but no new regulatory or efficacy milestone is disclosed.
Counterpoint
No efficacy/clinical benefit data are provided here; safety and antibody detection may not translate into meaningful plaque removal or cognitive outcomes.
Key entities
- companyAC Immune SA
Subject of the press release; reports interim ABATE Phase 1b/2 data for ACI-24 and AD4 adjuvant enhancement plan.
- product_candidateACI-24
Anti-amyloid beta active immunotherapy; interim data show general tolerability and antibody responses across doses.
- clinical_trialABATE trial
Randomized, double-blind, placebo-controlled Phase 1b/2 study; interim results reported for AD1-3 and AD4 initiation described.
- partnerTakeda
Has an exclusive worldwide option/license agreement for anti-Abeta active immunotherapies including ACI-24; milestone tied to AD4 dosing is disclosed.
.jpg%253Fdisable%253Dupscale%2526width%253D1200%2526height%253D630%2526fit%253Dcrop&w=3840&q=75)